BioCardia to Present at 2015 Stem Cell Meeting on the Mesa

October 06, 2015

SAN CARLOS, CA (GlobeNewswire) – BioCardia, Inc., a clinical-stage regenerative medicine company developing novel therapeutics for cardiovascular diseases announced today that Peter Altman, Chief Executive Officer will present at the annual Partnering Forum of the Stem Cell Meeting on the Mesa to be held October 7-9 in La Jolla, California.

Event:

2015 Stem Cell Meeting on the Mesa – Partnering Forum

Date: 

October 07, 2015

Time: 

1:30 p.m. PDT

Location: 

Estancia La Jolla Hotel & Spa
9700 North Torrey Pines Road, La Jolla, CA 92037

A live video webcast will be available here. Please visit this site for full information.

This conference brings together senior executives and top decision makers in the industry within the scientific community with the shared goal of advancing and translating cutting-edge research into revolutionary treatments and cures.


About BioCardia, Inc.
BioCardia is developing proprietary comprehensive biotherapeutic solutions for cardiovascular disease in its CardiAMP™ and CardiALLO™ cell therapies. Clinical results supporting both therapeutic programs are compelling and build upon the most rigorous data in the field to date with intramyocardial delivery of marrow-derived cells. These programs are enabled by the Company's Helix™ transendocardial delivery systems and Morph® vascular access products, which are partnered to enable other promising biotherapeutic programs.

Contact:
Miranda Peto Benvenuti MPeto@BioCardia.com

News

01 Dec

Empowered Patient Podcast

Optimizing Autologous Cell Therapy to Treat Cardiovascular Disease with Dr. Peter Altman
Read More
29 Oct

UW Health

UW Health Treats First Patient in U.S. with Investigational Cell Therapy for Heart Disease
Read More
29 Oct

Greenbay CBS

Neenah musician, educator pursues dream after being first in the world to undergo ‘Investigational Cell Therapy’
Read More
29 Oct

WBay.com

Neenah man gets new lease on life after trial heart procedure
Read More
04 Mar

Henry Ford Health System

Henry Ford Health System Studies Novel Cell Therapy Aimed at Improving Heart Failure Symptoms
Read More
08 Feb

Cell & Gene

Inside BioCardia's CardiAMP Cell Therapy
Read More

press releases

10 Jan
2022 BioCardia Announces Participation at the Upcoming Digital Medicine & Medtech Showcase and the H.C. Wainwright BioConnect Virtual Conference
15 Dec
2021 BioCardia Establishes New Manufacturing Facility to Enable Its Cell Therapy Product Candidates
10 Nov
2021 BioCardia Reports Third Quarter 2021 Financial Results and Business Highlights
08 Nov
2021 BioCardia To Release Third Quarter 2021 Financial Results November 10, 2021
21 Oct
2021 BioCardia Announces First Patient Treated in CardiAMP Cell Therapy Trial for Chronic Myocardial Ischemia
12 Oct
2021 BioCardia Issued New U.S. Patent for Technology that Enhances Control for Interventional Catheter Based Therapies
Have questions?
CALL US NOW
: (800) 624-1179
Have questions?
EMAIL US NOW
: info@biocardia.com

biocardia takes a new and comprehensive
approach to heart failure

By introducing patient screening and highly-efficient delivery to stem cell therapy, the company seeks to increase the likelihood of treatment success, enabling more patients to return to the things they love.
CLINICAL TRIALS